UCL Discovery
Performance of multi-parametric MRI in men at risk of prostate cancer prior to first biopsy: a paired validating cohort study using template prostate mapping biopsies as reference standardMohamed Abd-Alazeez1, Alex Kirkham2, Hashim U. Ahmed1,3, Manit Arya1,7, Eleni Anastasiadis5, Susan C. Charman4, Alex Freeman6, Mark Emberton1,31. Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK 2. Department of Radiology, University College Hospitals NHS Foundation Trust, London, UK3. Division of Surgery and Interventional Science, University College London, London, UK4. Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine 5. Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK6. Department of Histopathology, University College Hospitals NHS Foundation Trust, London, UK7. Barts Cancer Institute Keywords:Clinically significant disease, multi-parametric MRI, pre-biopsy, prostate cancer, Template prostate mapping, triage test, transrectal ultrasound guided biopsyAddress for correspondenceMohamed Abd-Alazeez67-73 Riding House StreetDivision of Surgery and Interventional ScienceUniversity College London, London, W1W 7EJ, London, UKTel 020 3447 9194Fax 020 3447 9303E-mail: mohamed.azeez.10@ucl.ac.ukAbstractBackground: Multi-parametric MRI (mp-MRI) has the potential to serve as a non-invasive triage test for men at risk of prostate cancer. Our objective was to determine the performance characteristics of multi-parametric MRI (mpMRI) in men at risk prior to first biopsy using 5mm template prostate mapping (TPM) as the reference standard.Methods: One hundred and twenty nine consecutive men with clinical suspicion of prostate cancer that had no prior biopsy, underwent mpMRI (T1/T2-weighted, diffusion-weighting, dynamic-contrast enhancement) followed by TPM. The primary analysis used: a) radiological scores of suspicion of ≥3 attributed from a 5-point ordinal scale, b) a target condition on TPM of any Gleason pattern ≥4 and/or a maximum cancer core length of ≥4mm and c) two sectors of analysis per prostate (right and left prostate halves). Secondary analyses evaluated the impact of: a) changing the mpMRI score threshold to ≥4 and b) varying the target definition for clinical significance. Results: 141/258 (55%) sectors of analysis showed “Any cancer”; 77/258 (30%) had the target histological condition for the purpose of deriving the primary outcome. Median (with range) for age, PSA, gland volume and number of biopsies taken were 62 years (-41-82), 5.8ng/ml (1.2-20), 40ml (16-137) and 41 cores (20-93). For the primary outcome sensitivity, specificity, positive and negative predictive values and area under the receiver operating curve (with 95% CI) were 94% (88-99%), 23% (17-29%), 34% (28-40%), 89% (79-98%) and 0.72 (0.65-0.79), respectively. Conclusion: MpMRI demonstrated encouraging diagnostic performance characteristics in detecting and ruling-out clinically significant prostate cancer in men at risk who were biopsy naive.IntroductionThere are a number of problems with the current prostate cancer diagnostic pathway that relies on serum prostate specific antigen (PSA) and transrectal ultrasound (TRUS) guided biopsy. Over-diagnosis and over-treatment have been a recognized consequence, but missed diagnosis and poor risk stratification also occur PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TY2hyb2RlcjwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TY2hyb2RlcjwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+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ADDIN EN.CITE.DATA 1,2. The only widely accepted correction has been to adopt the strategy of increased sampling ADDIN EN.CITE <EndNote><Cite><Author>Taylor</Author><Year>2002</Year><RecNum>127</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>John A. Taylor</author><author>Gancarczyk, Kevin J.</author><author>Fant, Gregory V.</author><author>McLeod, David G.</author></authors></contributors><titles><title>Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer</title><secondary-title>Urology</secondary-title></titles><periodical><full-title>Urology</full-title></periodical><pages>841-845</pages><volume>60</volume><number>5</number><dates><year>2002</year></dates><urls></urls></record></Cite></EndNote>3.An alternative strategy is to identify an area or volume of tissue at high probability of being cancer and target this area at biopsy, either exclusively or at a higher sampling density than the rest of the tissue. Multi-parametric MRI (mpMRI) currently holds the most promise for meeting the requirements of an imaging test which may be able to discriminate clinically significant cancer from areas with no cancer or clinically insignificant cancer within the prostate ADDIN EN.CITE <EndNote><Cite><Author>Ahmed</Author><Year>2009</Year><RecNum>3</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="2vr9tzr56ptze7ewdv65e9ai0ptwraw9vdxt">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ahmed, Hashim U</author><author>Kirkham, Alex</author><author>Arya, Manit</author><author>Illing, Rowland</author><author>Freeman, Alex</author><author>Allen, Clare</author><author>Emberton, Mark</author></authors></contributors><auth-address>Division of Surgical and Interventional Sciences, University College London, UK. hashim.ahmed@ucl.ac.uk</auth-address><titles><title>Is it time to consider a role for MRI before prostate biopsy?</title><secondary-title>Nature reviews. Clinical oncology</secondary-title></titles><pages>197-206</pages><volume>6</volume><number>4</number><dates><year>2009</year><pub-dates><date>May</date></pub-dates></dates><label>r00758</label><work-type>Review</work-type><urls><related-urls><url> of the studies to date have used transrectal biopsy as a reference test (which is limited in accuracy), targeted biopsies (which prevents systematic interrogation of negative areas) or radical prostatectomy (which introduces a selection bias in that men have to be histologically diagnosed with cancer and then choose surgery rather than radiotherapy or active surveillance). Transperineal template prostate mapping (TPM) biopsies offer a robust reference standard as the sampling frame is fixed at every 5mm of the whole prostate, allow systematic interrogation of the whole prostate, blinded to the imaging, can be applied to most men undergoing the index imaging test and therefore limit the selection bias. Recently, TPM biopsies have been shown to have little to no miss-classification error when compared to whole-mount radical prostatectomy pathology in the detection of lesions 0.5cc or greater in volume with or without the presence of Gleason pattern 4 or greaterPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DcmF3Zm9yZDwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DcmF3Zm9yZDwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE.DATA 5, reinforcing earlier simulation studies HYPERLINK \l "_ENREF_6" \o "Hu, 2012 #2589"PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IdTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJlY051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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IdTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJlY051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ADDIN EN.CITE.DATA 6. In this study, we aimed to answer the following question: In men with no previous biopsy who present with a clinical suspicion of prostate cancer (based on high PSA, positive family history and/or abnormal digital rectal examination), to what extent can mpMRI detect and rule-out clinically significant prostate cancer using TPM biopsies as the reference standard, in a real practice setting?Patients and methodsResearch ethics committee exemption was granted. In the period 01/01/2007 to 31/01/2011, men with a clinical suspicion of prostate cancer underwent a mpMRI; those with mpMRI scores of 3 or greater were offered a template mapping biopsy. One hundred and twenty-nine consecutive men were eligible for inclusion in this study as they all had an overall MRI score of ≥3 followed by TPM.Exclusion criteria included: a) prior biopsy, b) previous treatment for prostate cancer, c) PSA >20ng/ml (TPM would have been too invasive for such patients where limited TRUS sampling would suffice), d) >12 months between MRI and TPM, e) patients that did not have TPM, and f) patients that had inconclusive TPM where only limited numbers of biopsies were taken. MRIWe aimed to determine the performance of real-practice mpMRI prior to biopsy and therefore did not select cases based on type of MRI scanner used or whether certain radiology reporters were involved. The index test, mpMRI, comprised T2 weighted (T2W), Diffusion-weighted (DW) and Dynamic contrast enhanced (DCE) imaging with either 1.5 Tesla (Siemens Avanto, n=113) or 3.0 Tesla (Phillips Achieva n=16) magnetic field strengths (Table 1). A multi-channel (at least 8) pelvic phased array coil, but no endorectal coil, was used. The detailed scan parameters for the 1.5T machine are shown in Table 1; the slice thickness at 3T was identical, but the in-plane resolution was slightly better. The contrast used was 20ml of Gadoteric Acid 0.5mmol/ml (Dotarem, Guerbet, France) given by an automated injector coincident with the start of the third dynamic sequence. Our practice for the last 8 years has been to use only a pelvic phased array coil rather than an endorectal coil. This is in keeping with a number of other centres which undertake mpMRI for prostate cancer detection ADDIN EN.CITE <EndNote><Cite><Author>Barentsz</Author><Year>2012</Year><RecNum>291</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="p9f9e2p9uvdpznezfe4vrts052xrrvrr0drf">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Barentsz, J. O.</author><author>Richenberg, J.</author><author>Clements, R.</author><author>Choyke, P.</author><author>Verma, S.</author><author>Villeirs, G.</author><author>Rouviere, O.</author><author>Logager, V.</author><author>Futterer, J. J.</author><author>European Society of Urogenital, Radiology</author></authors></contributors><auth-address>Department of Radiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. j.barentsz@rad.umcn.nl</auth-address><titles><title>ESUR prostate MR guidelines 2012</title><secondary-title>Eur Radiol</secondary-title><alt-title>European radiology</alt-title></titles><periodical><full-title>Eur Radiol</full-title><abbr-1>European radiology</abbr-1></periodical><alt-periodical><full-title>Eur Radiol</full-title><abbr-1>European radiology</abbr-1></alt-periodical><pages>746-57</pages><volume>22</volume><number>4</number><keywords><keyword>Europe</keyword><keyword>Humans</keyword><keyword>Magnetic Resonance Imaging/*standards</keyword><keyword>Male</keyword><keyword>Medical Oncology/*standards</keyword><keyword>Prostatic Neoplasms/*diagnosis</keyword><keyword>Radiology/*standards</keyword><keyword>Urology/*standards</keyword></keywords><dates><year>2012</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>1432-1084 (Electronic)
0938-7994 (Linking)</isbn><accession-num>22322308</accession-num><urls><related-urls><url> radiologists (each one is reporting at least 100 prostate mpMRIs per year) reported all the mpMR images using a score from 1 to 5 as in the recent European Consensus Guidelines ADDIN EN.CITE <EndNote><Cite><Author>Barentsz</Author><Year>2012</Year><RecNum>291</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="p9f9e2p9uvdpznezfe4vrts052xrrvrr0drf">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Barentsz, J. O.</author><author>Richenberg, J.</author><author>Clements, R.</author><author>Choyke, P.</author><author>Verma, S.</author><author>Villeirs, G.</author><author>Rouviere, O.</author><author>Logager, V.</author><author>Futterer, J. J.</author><author>European Society of Urogenital, Radiology</author></authors></contributors><auth-address>Department of Radiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. j.barentsz@rad.umcn.nl</auth-address><titles><title>ESUR prostate MR guidelines 2012</title><secondary-title>Eur Radiol</secondary-title><alt-title>European radiology</alt-title></titles><periodical><full-title>Eur Radiol</full-title><abbr-1>European radiology</abbr-1></periodical><alt-periodical><full-title>Eur Radiol</full-title><abbr-1>European radiology</abbr-1></alt-periodical><pages>746-57</pages><volume>22</volume><number>4</number><keywords><keyword>Europe</keyword><keyword>Humans</keyword><keyword>Magnetic Resonance Imaging/*standards</keyword><keyword>Male</keyword><keyword>Medical Oncology/*standards</keyword><keyword>Prostatic Neoplasms/*diagnosis</keyword><keyword>Radiology/*standards</keyword><keyword>Urology/*standards</keyword></keywords><dates><year>2012</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>1432-1084 (Electronic)
0938-7994 (Linking)</isbn><accession-num>22322308</accession-num><urls><related-urls><url>, which have recently been validated ADDIN EN.CITE <EndNote><Cite><Author>Portalez</Author><Year>2012</Year><RecNum>2205</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>2205</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">2205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Portalez, D.</author><author>Mozer, P.</author><author>Cornud, F.</author><author>Renard-Penna, R.</author><author>Misrai, V.</author><author>Thoulouzan, M.</author><author>Malavaud, B.</author></authors></contributors><auth-address>Departments of Radiology, Clinique Pasteur, Toulouse, France.</auth-address><titles><title>Validation of the European society of urogenital radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients</title><secondary-title>Eur Urol</secondary-title></titles><periodical><full-title>Eur Urol</full-title></periodical><pages>986-96</pages><volume>62</volume><number>6</number><edition>2012/07/24</edition><dates><year>2012</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1873-7560 (Electronic)
0302-2838 (Linking)</isbn><accession-num>22819387</accession-num><urls><related-urls><url>(12)00757-9 [pii]
10.1016/j.eururo.2012.06.044</electronic-resource-num><language>eng</language></record></Cite></EndNote>8: 1= Clinically significant disease is highly unlikely to be present, 2= Clinically significant disease is unlikely to be present, 3= Clinically significant disease is equivocal, 4= Clinically significant disease is likely to be present, 5= Clinically significant disease is highly likely. MRI Images from each patient were reviewed by one radiologist. The index test was conducted in a blinded manner to the reference test as all mpMRI reports were committed to the electronic medical record prior to the biopsy result becoming available. Some reports (n=38) did not contain numerical scoring data and for these, one designated reporter (AK) provided numerical scores based only on the report text and blinded to histology. Whenever a suspected lesion crossed the midline, both prostate halves (right and left) were attributed the same scoring for that lesion. As the role of mpMRI in future may be to triage men and thus select those that could avoid a biopsy, we incorporated the uncertainty score of ‘3’ to confer a positive index test; thus, mpMRI scores of ≥3 were designated positive for the purpose of the primary outcome. The effect of varying this threshold to ≥4 was also evaluated as a secondary outcome. If the mpMRI was positive in an area proven to harbor clinically insignificant disease, according to the definition used, this area was deemed as false positive. BiopsyAll patients underwent TPM biopsies using a 5mm sampling frame under general anesthesia in the method previously described by Barzell ADDIN EN.CITE <EndNote><Cite><Author>Barzell</Author><Year>2007</Year><RecNum>125</RecNum><DisplayText><style face="superscript">9</style></DisplayText><record><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Winston E. Barzell</author><author>Melamed, Myron R.</author></authors></contributors><titles><title>Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-Dimensional pathologic mapping of the prostate—a 4-year experience</title><secondary-title>Urology</secondary-title></titles><periodical><full-title>Urology</full-title></periodical><pages>27-35</pages><volume>70</volume><number>Suppl 6A</number><dates><year>2007</year></dates><urls></urls></record></Cite></EndNote>9. Urologists doing TPM biopsies were not blinded to MRI results however all 20 zones of the prostate were systematically biopsied. Target conditions: The pathological outputs from the reference test were grouped into a number of definitions of clinical significance, or target conditions, in order to reflect the fact that no universally accepted definition currently exists. These “Target Conditions” are:UCL definition 1: Gleason ≥ 4+3 and/or maximum cancer core length (CCLmax) ≥ 6mmUCL definition 2: Gleason ≥ 3+4 and/or maximum cancer core length (CCLmax) ≥ 4mmGleason score ≥ 4+3Gleason score ≥ 3+4CCLmax ≥ 6mmCCLmax ≥ 4mmThe target histological condition for the purpose of deriving our primary outcome is one that is used in other large-scale multicenter level I evidence validating cohort studies in which mpMRI is being compared to TPM ADDIN EN.CITE <EndNote><Cite><Author>Simmons</Author><Year>2011</Year><RecNum>245</RecNum><DisplayText><style face="superscript">10,11</style></DisplayText><record><rec-number>245</rec-number><foreign-keys><key app="EN" db-id="p9f9e2p9uvdpznezfe4vrts052xrrvrr0drf">245</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Simmons, Lucy</author><author>Ahmed, H. U,</author><author>Moore, C. M,</author><author>Emberton, M.</author></authors></contributors><titles><title>Imaging for Significant Prostate Cancer Risk Evaluation (PICTURE)</title></titles><volume>2013</volume><number>08 July</number><dates><year>2011</year></dates><publisher></publisher><urls><related-urls><url> app="EN" db-id="p9f9e2p9uvdpznezfe4vrts052xrrvrr0drf">246</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Emberton, M.</author></authors></contributors><titles><title>PROMIS - Prostate MRI Imaging Study - Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterization of Prostate Cancer</title></titles><volume>2013</volume><number>08 July</number><dates><year>2011</year></dates><publisher></publisher><urls><related-urls><url>. The histological reporting in our institution follows the classic scheme of interpreting the Gleason grading, the one used before the International Society of Urological Pathology 2005 guidelines ADDIN EN.CITE <EndNote><Cite><Author>Epstein</Author><Year>2005</Year><RecNum>134</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Jonathan I. Epstein</author><author>Allsbrook, William C.</author><author>Amin, Mahul B.</author><author>Egevad, Lars L.</author></authors></contributors><titles><title>The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma.</title><secondary-title>Am J Surg Pathol</secondary-title></titles><periodical><full-title>Am J Surg Pathol</full-title></periodical><pages>1228-1242</pages><volume>29</volume><number>9</number><dates><year>2005</year></dates><urls></urls></record></Cite></EndNote>12. In other words, Gleason scoring was based on the most frequent pattern, and not the highest grade, detected on histological analysis (although the latter was always available for each TPM zone). Further, the cancer core length was reported as the actual amount of cancer seen in each core without counting the intervening areas of benign glands HYPERLINK \l "_ENREF_13" \o "Karram, 2011 #90"PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXJyYW08L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS
ZWNOdW0+OTA8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4x
Mzwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjkwPC9yZWMtbnVtYmVy
Pjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0icDlmOWUycDl1dmRwem5lemZlNHZy
dHMwNTJ4cnJ2cnIwZHJmIj45MDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK
b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo
b3I+S2FycmFtLCBTLjwvYXV0aG9yPjxhdXRob3I+VHJvY2ssIEIuIEouPC9hdXRob3I+PGF1dGhv
cj5OZXR0bywgRy4gSi48L2F1dGhvcj48YXV0aG9yPkVwc3RlaW4sIEouIEkuPC9hdXRob3I+PC9h
dXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBQYXRob2xv
Z3ksIFRoZSBKb2hucyBIb3BraW5zIEhvc3BpdGFsLCA0MDEgTi4gQnJvYWR3YXkgU3RyZWV0LCBC
YWx0aW1vcmUsIE1EIDIxMjMxLCBVU0EuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+U2hv
dWxkIGludGVydmVuaW5nIGJlbmlnbiB0aXNzdWUgYmUgaW5jbHVkZWQgaW4gdGhlIG1lYXN1cmVt
ZW50IG9mIGRpc2NvbnRpbnVvdXMgZm9jaSBvZiBjYW5jZXIgb24gcHJvc3RhdGUgbmVlZGxlIGJp
b3BzeT8gQ29ycmVsYXRpb24gd2l0aCByYWRpY2FsIHByb3N0YXRlY3RvbXkgZmluZGluZ3M8L3Rp
dGxlPjxzZWNvbmRhcnktdGl0bGU+QW0gSiBTdXJnIFBhdGhvbDwvc2Vjb25kYXJ5LXRpdGxlPjxh
bHQtdGl0bGU+VGhlIEFtZXJpY2FuIGpvdXJuYWwgb2Ygc3VyZ2ljYWwgcGF0aG9sb2d5PC9hbHQt
dGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0gSiBTdXJnIFBhdGhvbDwv
ZnVsbC10aXRsZT48YWJici0xPlRoZSBBbWVyaWNhbiBqb3VybmFsIG9mIHN1cmdpY2FsIHBhdGhv
bG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0g
SiBTdXJnIFBhdGhvbDwvZnVsbC10aXRsZT48YWJici0xPlRoZSBBbWVyaWNhbiBqb3VybmFsIG9m
IHN1cmdpY2FsIHBhdGhvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjEzNTEt
NTwvcGFnZXM+PHZvbHVtZT4zNTwvdm9sdW1lPjxudW1iZXI+OTwvbnVtYmVyPjxrZXl3b3Jkcz48
a2V5d29yZD5BZGVub2NhcmNpbm9tYS9pbW11bm9sb2d5LypwYXRob2xvZ3kvc3VyZ2VyeTwva2V5
d29yZD48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3
b3JkPkJhbHRpbW9yZTwva2V5d29yZD48a2V5d29yZD4qQmlvcHN5LCBOZWVkbGU8L2tleXdvcmQ+
PGtleXdvcmQ+Q2hpLVNxdWFyZSBEaXN0cmlidXRpb248L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5z
PC9rZXl3b3JkPjxrZXl3b3JkPkxvZ2lzdGljIE1vZGVsczwva2V5d29yZD48a2V5d29yZD5NYWxl
PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk5lb3BsYXNt
IFN0YWdpbmc8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20sIFJlc2lkdWFsPC9rZXl3b3JkPjxr
ZXl3b3JkPlByZWRpY3RpdmUgVmFsdWUgb2YgVGVzdHM8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25v
c2lzPC9rZXl3b3JkPjxrZXl3b3JkPlByb3N0YXRlLVNwZWNpZmljIEFudGlnZW4vYmxvb2Q8L2tl
eXdvcmQ+PGtleXdvcmQ+KlByb3N0YXRlY3RvbXk8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3RhdGlj
IE5lb3BsYXNtcy9pbW11bm9sb2d5LypwYXRob2xvZ3kvc3VyZ2VyeTwva2V5d29yZD48a2V5d29y
ZD5TdHJvbWFsIENlbGxzLypwYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VGltZSBGYWN0b3Jz
PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTE8L3llYXI+PHB1Yi1kYXRlcz48
ZGF0ZT5TZXA8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTMyLTA5NzkgKEVsZWN0
cm9uaWMpJiN4RDswMTQ3LTUxODUgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIxODM2
NDkzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5j
YmkubmxtLm5paC5nb3YvcHVibWVkLzIxODM2NDkzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxz
PjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDk3L1BBUy4wYjAxM2UzMTgyMjE3Yjc5PC9l
bGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXJyYW08L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS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=
ADDIN EN.CITE.DATA 13. Our target condition definitions is based on the only system that has been validated for a parallel sampling strategy and is based on the traditional volume and grade thresholds for individual lesions that are centred on 0.2cc and 0.5cc in combination with dominant and non-dominant Gleason pattern 4 PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BaG1lZDwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BaG1lZDwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl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ADDIN EN.CITE.DATA 14.Statistical considerationsAnalysis was done at half prostate level (right and left). This was done via drawing an imaginary sagital line that passes through the patient urethra and divides the prostate in two halves. This resulted in 258 sectors of analysis out of the 129 patients. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and the area under the receiver operating characteristic curve (AUROC) are presented with 95% confidence intervals (95% CI). Confidence intervals were obtained by bootstrapping using 500 bootstrap samples in order to account for the fact that these sectors of analysis were not independent of each other ADDIN EN.CITE <EndNote><Cite><Author>Efron</Author><Year>1993</Year><RecNum>1921</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>1921</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">1921</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>Bradley Efron</author><author>Tibshirani, Robert J.</author></authors></contributors><titles><title>An Introduction to the Bootstrap (Chapman & Hall/CRC Monographs on Statistics & Applied Probability)</title></titles><dates><year>1993</year></dates><urls></urls></record></Cite></EndNote>15.Our predefined primary objective was to assess the ability of mpMRI (with a score of ≥3/5 considered positive) to detect and rule-out clinically significant disease, defined as any cancer with Gleason pattern 4 or greater (≥3+4) and/or maximum cancer core length (CCLmax ≥4mm]) (UCL definition 2), in one prostate half (right or left).Our predefined secondary objectives were to examine the performance of the index test by a) changing the mpMRI score threshold to ≥4 and b) varying the target histological definition for clinical significance .ResultsBaseline demographic data are presented in Table 2. Primary outcomeIn ruling-out UCL definition 2 clinically significant cancer, mpMRI had a sensitivity and NPV of 94% (95% CI, 88-99%) and 89% (95% CI, 79-98%), respectively (Table 3). In ruling in UCL definition 2 cancer, mpMRI had a specificity and PPV of 23% (95% CI, 17-29%) and 34% (95% CI, 28-40%), respectively.Secondary outcomesThe performance of the test for different levels of clinical significance on TPM at mpMRI threshold of ≥3 is shown in Table 3. The sensitivity for the detection of Gleason 4+3 disease using an mpMRI score of ≥3 was 100%.When using an mpMRI score of ≥4 to rule-out UCL definition 2 cancer, we had lower sensitivity of 68% (95% CI, 56-78%) with reduction in NPV (83% [95% CI, 77-89%]) (this is not a significant decrease). In ruling-in UCL definition 2 cancer at an mpMRI score of ≥4, both specificity (69% [95% CI, 61-76%]) and PPV (48% [95% CI, 38-58%]) improved. The results for other definitions of significance are shown in Table 4.Table 5 shows AUROC curve values for different definitions of clinically significant disease at mpMRI scores 1-5.DiscussionSummary of ResultsThe accuracy of mpMRI at detecting clinically significant prostate cancer varied with the mpMRI threshold that was used to declare a lesion as being present or absent. If the indeterminate score of 3 was included as a positive mpMRI, high sensitivity (93-100%) and NPV (89-100%) were achieved, but with low specificity (19-23%) and PPV (6-34%). When the indeterminate state was omitted and mpMRI scores of 4 and 5 only were used, specificity (61-69%) and PPV (11-48%) improved substantially whilst only marginally compromising sensitivity (68-92%) and NPV (83-99%). The choice of threshold depends on the purpose of the test. Some have argued that the greatest clinical utility for mpMRI is as a triage test to rule-out clinically significant prostate cancer so that men can avoid biopsies or reduce the burden of biopsy in areas that are negative on imaging. For this purpose, the NPV of 89-100% that we have demonstrated (with negative defined as a radiological score of 1 or 2) would add some weight to this argument.The low specificities that we have demonstrated are in part a consequence of applying our definitions of clinical significance on histology rigidly. In other words, even if cancer was found in the mpMRI suspicious area it would be discounted as a false positive if the amount or grade did not meet the pre-specified threshold for clinical significance; others have considered any cancer detected in MRI suspicious areas as true positives regardless of burden of disease found. ADDIN EN.CITE <EndNote><Cite><Author>Puech</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="p9f9e2p9uvdpznezfe4vrts052xrrvrr0drf">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Puech, P.</author><author>Potiron, E.</author><author>Lemaitre, L.</author><author>Leroy, X.</author><author>Haber, G. P.</author><author>Crouzet, S.</author><author>Kamoi, K.</author><author>Villers, A.</author></authors></contributors><auth-address>Department of Radiology, Centre Hospitalier Regional Universitaire de Lille, France.</auth-address><titles><title>Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens</title><secondary-title>Urology</secondary-title><alt-title>Urology</alt-title></titles><periodical><full-title>Urology</full-title><abbr-1>Urology</abbr-1></periodical><alt-periodical><full-title>Urology</full-title><abbr-1>Urology</abbr-1></alt-periodical><pages>1094-9</pages><volume>74</volume><number>5</number><keywords><keyword>Aged</keyword><keyword>*Contrast Media</keyword><keyword>Humans</keyword><keyword>*Magnetic Resonance Imaging/methods</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>*Prostatectomy</keyword><keyword>Prostatic Neoplasms/*pathology/*surgery</keyword></keywords><dates><year>2009</year><pub-dates><date>Nov</date></pub-dates></dates><isbn>1527-9995 (Electronic)
0090-4295 (Linking)</isbn><accession-num>19773038</accession-num><urls><related-urls><url>. As a result, our method will inevitably lead to an overestimate of false positives: small lesions correctly scored as likely tumours on mpMRI will count as false positives because they did not meet the histological criteria for parison with other studiesFigures for NPV depend greatly on the population being studied and the method of analysis. It is, however, reassuring that another group found a very high NPV for high grade (dominant Gleason 4) tumours of 98.4% PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WaWxsZWlyczwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5WaWxsZWlyczwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+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ADDIN EN.CITE.DATA 17 using T2 and spectroscopy sequences. Other studies using whole-mount prostatectomy as reference standard support the proposition that mpMRI has encouragingly high performance characteristics for detecting and ruling-out clinically significant prostate cancer ADDIN EN.CITE <EndNote><Cite><Author>Turkbey</Author><Year>2011</Year><RecNum>2616</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>2616</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">2616</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Turkbey, B.</author><author>Mani, H.</author><author>Shah, V.</author><author>Rastinehad, A. R.</author><author>Bernardo, M.</author><author>Pohida, T.</author><author>Pang, Y.</author><author>Daar, D.</author><author>Benjamin, C.</author><author>McKinney, Y. L.</author><author>Trivedi, H.</author><author>Chua, C.</author><author>Bratslavsky, G.</author><author>Shih, J. H.</author><author>Linehan, W. M.</author><author>Merino, M. J.</author><author>Choyke, P. L.</author><author>Pinto, P. A.</author></authors></contributors><auth-address>Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.</auth-address><titles><title>Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds</title><secondary-title>J Urol</secondary-title></titles><periodical><full-title>J Urol</full-title></periodical><pages>1818-24</pages><volume>186</volume><number>5</number><edition>2011/09/29</edition><dates><year>2011</year><pub-dates><date>Nov</date></pub-dates></dates><isbn>1527-3792 (Electronic)
0022-5347 (Linking)</isbn><accession-num>21944089</accession-num><urls><related-urls><url>(11)04362-X [pii]
10.1016/j.juro.2011.07.013</electronic-resource-num><language>eng</language></record></Cite></EndNote>18.Controversy continues on the use of endorectal coils, 3T machines and the relative value of the different components of a ‘multi-parametric’ scan. However, there is increasing evidence that both DW and DCE improve the performance of the test HYPERLINK \l "_ENREF_19" \o "Tanimoto, 2007 #2501"PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UYW5pbW90bzwvQXV0aG9yPjxZZWFyPjIwMDc8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UYW5pbW90bzwvQXV0aG9yPjxZZWFyPjIwMDc8L1llYXI+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ADDIN EN.CITE.DATA 19-22. In our institution, we achieved similar results to groups using endorectal coil. According to the recently published ESUR guidelines ADDIN EN.CITE <EndNote><Cite><Author>Barentsz</Author><Year>2012</Year><RecNum>291</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="p9f9e2p9uvdpznezfe4vrts052xrrvrr0drf">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Barentsz, J. O.</author><author>Richenberg, J.</author><author>Clements, R.</author><author>Choyke, P.</author><author>Verma, S.</author><author>Villeirs, G.</author><author>Rouviere, O.</author><author>Logager, V.</author><author>Futterer, J. J.</author><author>European Society of Urogenital, Radiology</author></authors></contributors><auth-address>Department of Radiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. j.barentsz@rad.umcn.nl</auth-address><titles><title>ESUR prostate MR guidelines 2012</title><secondary-title>Eur Radiol</secondary-title><alt-title>European radiology</alt-title></titles><periodical><full-title>Eur Radiol</full-title><abbr-1>European radiology</abbr-1></periodical><alt-periodical><full-title>Eur Radiol</full-title><abbr-1>European radiology</abbr-1></alt-periodical><pages>746-57</pages><volume>22</volume><number>4</number><keywords><keyword>Europe</keyword><keyword>Humans</keyword><keyword>Magnetic Resonance Imaging/*standards</keyword><keyword>Male</keyword><keyword>Medical Oncology/*standards</keyword><keyword>Prostatic Neoplasms/*diagnosis</keyword><keyword>Radiology/*standards</keyword><keyword>Urology/*standards</keyword></keywords><dates><year>2012</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>1432-1084 (Electronic)
0938-7994 (Linking)</isbn><accession-num>22322308</accession-num><urls><related-urls><url>, Barentsz et al. recommended 3 different protocols for detection, staging and for nodes and bone metastases. In the detection protocol they advised with T2W + DW + DCE imaging without an endorectal coil. They added that this can adequately be done at 1.5T using 8-16 channel pelvic phased array.Most studies of MRI in the prostate have divided up the prostate into numerous sectors for analysis. While this has the advantage of increasing the number of data points, and enables the assessment of the performance of MR in different regions, it has fundamental drawbacks: edge effects increase with the number of sectors, and figures for specificity and NPV are not easy to interpret when reapplied to the level of the whole prostate ADDIN EN.CITE <EndNote><Cite><Author>Kirkham</Author><Year>2006</Year><RecNum>312</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>312</rec-number><foreign-keys><key app="EN" db-id="xvf9tsfsn0wracezpr95atsxtp5xa22dfsa9">312</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kirkham, A.</author><author>Emberton, M.</author><author>Allen, C.</author></authors></contributors><titles><title>How Good is MRI at Detecting and Characterising Cancer within the Prostate?</title><secondary-title>European Urology</secondary-title></titles><periodical><full-title>European Urology</full-title></periodical><pages>1163-1175</pages><volume>50</volume><number>6</number><dates><year>2006</year><pub-dates><date>Dec 1</date></pub-dates></dates><label>p00094</label><urls><pdf-urls><url>. We analysed the prostate in halves rather than wholes because of the high prevalence of disease in our cohort, but did not divide further into sectors, and the results are therefore directly relevant to some important clinical questions ADDIN EN.CITE <EndNote><Cite><Author>Ahmed</Author><Year>2012</Year><RecNum>1925</RecNum><DisplayText><style face="superscript">24</style></DisplayText><record><rec-number>1925</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">1925</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ahmed, H. U.</author><author>Hindley, R. G.</author><author>Dickinson, L.</author><author>Freeman, A.</author><author>Kirkham, A. P.</author><author>Sahu, M.</author><author>Scott, R.</author><author>Allen, C.</author><author>Van der Meulen, J.</author><author>Emberton, M.</author></authors></contributors><auth-address>Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.</auth-address><titles><title>Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study</title><secondary-title>Lancet Oncol</secondary-title></titles><periodical><full-title>Lancet Oncol</full-title></periodical><pages>622-32</pages><volume>13</volume><number>6</number><edition>2012/04/20</edition><dates><year>2012</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>1474-5488 (Electronic)
1470-2045 (Linking)</isbn><accession-num>22512844</accession-num><urls><related-urls><url>(12)70121-3 [pii]
10.1016/S1470-2045(12)70121-3</electronic-resource-num><language>eng</language></record></Cite></EndNote>24. We do believe however that with dividing the gland into further sectors for analysis, more selective ablation of the gland could be undertaken. However this is better performed through using TRUS-MRI image fusion with accurate localization of the targeted prostate cancer disease HYPERLINK \l "_ENREF_25" \o "Vourganti, 2012 #273"PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Wb3VyZ2FudGk8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Wb3VyZ2FudGk8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFy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ADDIN EN.CITE.DATA 25. Further, we accounted for adjacency by conducting boot-strap analyses.Clinical implicationsMost studies have used a dichotomous result to declare whether mpMRI is normal or abnormal. By applying an ordinal 5-point scale we can begin to explore the impact of incorporating indeterminate results within our definition of normal or abnormal. Our observation that the test result is sensitive to the probability threshold used may allow us to use mpMRI in a more intelligent manner than we had previously contemplated. What is the implication of a negative scan of one half of the prostate – in other words, an MRI score of 1-2, which occurred in 18% of prostate halves? In our population, the implication was a very high chance of that half being free of Gleason dominant 4 tumour (none were missed), a 93% chance of being free of any Gleason pattern 4 and a 98% chance that the CCLmax would be <6mm. If both prostate halves are negative, a decision to defer biopsy might seem reasonable if these data are substantiated in larger multicentre studies in which the unit of analysis is the whole prostate. We are currently conducting such a study.In contrast, if a mpMRI is attributed a score of 4 or 5 (Figure 1) then the probability of clinically significant disease will be around 50%, (though for any tumour 73%). Accounting for this apparently low figure are many tumours correctly identified on mpMRI but falling below the thresholds for clinical significance: in practice the level of PPV is useful with encouragingly high positive hit-rates with targeted biopsies using a limited number of cores HYPERLINK \l "_ENREF_26" \o "Haffner, 2011 #264"PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWZmbmVyPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWZmbmVyPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48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ADDIN EN.CITE.DATA 26-28.The indeterminate mpMRI remains a problem (Figure 2), though is an under-reported phenomenon HYPERLINK \l "_ENREF_29" \o "Rouse, 2011 #269"PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Sb3VzZTwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Sb3VzZTwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl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ADDIN EN.CITE.DATA 29. We usually see a score of 3 as a positive signal to biopsy, with the mpMRI findings still useful for targeting the equivocal area. However, if the aim of the scan is to rule-out large volume or high grade (Gleason dominant 4) disease, a score of 3 might prompt deferring the biopsy after a period of surveillance. Such decision-making will depend on a balance of patient factors such as age, comorbidity and competing mortality risk assessment as well as anxiety.Overall, if mpMRI can be used to defer or reduce the burden of biopsy in some patients, and to target suspicious foci in most others, it might serve as a rational triage test ADDIN EN.CITE <EndNote><Cite><Author>Ahmed</Author><Year>2009</Year><RecNum>3</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="2vr9tzr56ptze7ewdv65e9ai0ptwraw9vdxt">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ahmed, Hashim U</author><author>Kirkham, Alex</author><author>Arya, Manit</author><author>Illing, Rowland</author><author>Freeman, Alex</author><author>Allen, Clare</author><author>Emberton, Mark</author></authors></contributors><auth-address>Division of Surgical and Interventional Sciences, University College London, UK. hashim.ahmed@ucl.ac.uk</auth-address><titles><title>Is it time to consider a role for MRI before prostate biopsy?</title><secondary-title>Nature reviews. Clinical oncology</secondary-title></titles><pages>197-206</pages><volume>6</volume><number>4</number><dates><year>2009</year><pub-dates><date>May</date></pub-dates></dates><label>r00758</label><work-type>Review</work-type><urls><related-urls><url>. In addition, in the case of a positive diagnosis of tumour, the pre-biopsy mpMRI is immediately available for staging, and is free of post-biopsy artefact, which can reduce its accuracy.Our study had some limitations. The first relates to the nature of our study. We chose to analyze and report our real-life practice experience. We did this as one of the major critiques of mpMRI is that it can only be done within specialist units and rigid protocols. This criticism, if correct, compromises the external validity of some of the studies that have been published to date. Second, our cohort incorporated some work-up bias. Patients with an mpMRI score of 1 or 2 throughout the prostate tended not to choose TPM over TRUS biopsy. We could therefore not include them. Adding more to that is the use of TPM as a reference standard rather than TRUS biopsy. These factors lead to high prevalence of disease in our cohort. Since prevalence was high, one would expect to see a low NPV. However our NPV was 89-100% for different definitions of clinically significant disease. It is also known that the prevalence does not directly affect sensitivity and specificity whereas it affects positive and negative predictive values. Our sensitivity amongst different definitions of clinically significant disease was 93-100%.Third, despite the fact that template biopsies perform well for the detection of significant disease (both in theoretical studies and in practice ADDIN EN.CITE <EndNote><Cite><Author>Bittner</Author><Year>2013</Year><RecNum>26</RecNum><DisplayText><style face="superscript">30</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="taxa90fps2efw7ea52gxtzsiz0t02xzf0fd2">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bittner, N.</author><author>Merrick, G. S.</author><author>Butler, W. M.</author><author>Bennett, A.</author><author>Galbreath, R. W.</author></authors></contributors><auth-address>Tacoma/Valley Radiation Oncology Centers, Tacoma, WA.</auth-address><titles><title>Incidence And Pathologic Features Of Prostate Cancer Detected On Transperineal Template-Guided Mapping Biopsy Following Negative Transrectal Ultrasound-Guided Biopsy</title><secondary-title>J Urol</secondary-title></titles><edition>2013/02/19</edition><dates><year>2013</year><pub-dates><date>Feb 14</date></pub-dates></dates><isbn>1527-3792 (Electronic)
0022-5347 (Linking)</isbn><accession-num>23416641</accession-num><urls><related-urls><url>(13)00290-5 [pii]
10.1016/j.juro.2013.02.021</electronic-resource-num><language>Eng</language></record></Cite></EndNote>30 , with figures of up to 87% for the detection of significant tumour), they are arguably less accurate than radical prostatectomy, and we used a core biopsy technique to estimate tumour significance. Although the technique for doing so has been validated HYPERLINK \l "_ENREF_14" \o "Ahmed, 2011 #247"PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BaG1lZDwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BaG1lZDwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl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ADDIN EN.CITE.DATA 14, it introduces another potential source of error.Finally, although it is widely recognized that not all prostate cancer requires treatment ADDIN EN.CITE <EndNote><Cite><Author>Ahmed</Author><Year>2009</Year><RecNum>336</RecNum><DisplayText><style face="superscript">31</style></DisplayText><record><rec-number>336</rec-number><foreign-keys><key app="EN" db-id="pfar9w2x652pfeevww9papxhxfp5ev9tfwav">336</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ahmed, H. U.</author></authors></contributors><auth-address>Division of Surgery and Interventional Sciences, University College, and the National Institute for Health Research-Comprehensive Biomedical Research Centre, University College Hospital, London.</auth-address><titles><title>The index lesion and the origin of prostate cancer</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>1704-6</pages><volume>361</volume><number>17</number><edition>2009/10/23</edition><keywords><keyword>Humans</keyword><keyword>Male</keyword><keyword>*Neoplasm Metastasis/genetics/pathology</keyword><keyword>Prognosis</keyword><keyword>Prostatic Neoplasms/genetics/*pathology/therapy</keyword></keywords><dates><year>2009</year><pub-dates><date>Oct 22</date></pub-dates></dates><isbn>1533-4406 (Electronic)
0028-4793 (Linking)</isbn><accession-num>19846858</accession-num><urls><related-urls><url> [pii]
10.1056/NEJMcibr0905562</electronic-resource-num><language>eng</language></record></Cite></EndNote>31, the definitions of clinically significant disease are inevitably contentious. We attempted to include as many as possible to allow for the differences of opinion that currently exist, especially with regard to Gleason 4 disease PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QbG91c3NhcmQ8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFy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 EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QbG91c3NhcmQ8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFy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 EN.CITE.DATA 32,33.ConclusionA normal multi-parametric MRI – that is, one with a score of 1 or 2 - confers a high probability (89-100%) of freedom from clinically significant prostate cancer and as a result, may allow some men to defer or reduce the burden of prostate biopsy. The positive predictive value for clinically significant disease – that is, lesions scoring 4 or 5 on mpMRI – was approximately 50%, something which may allow these patients to benefit from targeted biopsy. AcknowledgementsMohamed Abd-Alazeez receives funding from the Egyptian government. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK and St Peter’s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK. Manit Arya would like to acknowledge Orchid (male cancer charity) and Barts and London charity.Conflict of interest:None of the funding sources had any role in the data acquisition, analyses and production of this manuscript. Other sources of fundingMark Emberton and Hashim U Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant to Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. References ADDIN EN.REFLIST 1.Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13): 1320-1328.2.Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11(8): 725-732.3.Taylor JA, Gancarczyk KJ, Fant GV, McLeod DG. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002; 60(5): 841-845.4.Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C et al. Is it time to consider a role for MRI before prostate biopsy? Nature reviews Clinical oncology 2009; 6(4): 197-206.5.Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. The Prostate 2013; 73(7): 778-787.6.Hu Y, Ahmed HU, Carter T, Arumainayagam N, Lecornet E, Barzell W et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012; 110(6): 812-820.7.Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G et al. ESUR prostate MR guidelines 2012. European radiology 2012; 22(4): 746-757.8.Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M et al. Validation of the European society of urogenital radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012; 62(6): 986-996.9.Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-Dimensional pathologic mapping of the prostate—a 4-year experience. Urology 2007; 70(Suppl 6A): 27-35.10.Simmons L, Ahmed HU, Moore CM, Emberton M. Imaging for Significant Prostate Cancer Risk Evaluation (PICTURE). , 2011.11.Emberton M. PROMIS - Prostate MRI Imaging Study - Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterization of Prostate Cancer. , 2011.12.Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29(9): 1228-1242.13.Karram S, Trock BJ, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. The American journal of surgical pathology 2011; 35(9): 1351-1355.14.Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. The Journal of urology 2011; 186(2): 458-464.15.Efron B, Tibshirani RJ. An Introduction to the Bootstrap (Chapman & Hall/CRC Monographs on Statistics & Applied Probability), 1993.16.Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009; 74(5): 1094-1099.17.Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. European journal of radiology 2011; 77(2): 340-345.18.Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186(5): 1818-1824.19.Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. Journal of magnetic resonance imaging : JMRI 2007; 25(1): 146-152.20.Isebaert S, Van den Bergh L, Haustermans K, Joniau S, Lerut E, De Wever L et al. Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. Journal of magnetic resonance imaging : JMRI 2013; 37(6): 1392-1401.21.Akin O, Gultekin DH, Vargas HA, Zheng J, Moskowitz C, Pei X et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. European radiology 2011; 21(9): 1970-1978.22.Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan N, Zerbib M et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate cancer and prostatic diseases 2011; 14(3): 232-237.23.Kirkham A, Emberton M, Allen C. How Good is MRI at Detecting and Characterising Cancer within the Prostate? European Urology 2006; 50(6): 1163-1175.24.Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13(6): 622-632.25.Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. The Journal of urology 2012; 188(6): 2152-2157.26.Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU international 2011; 108(8 Pt 2): E171-178.27.Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. The Journal of urology 2013; 189(3): 860-866.28.Delongchamps NB, Peyromaure M, Schull A, Beuvon F, Bouazza N, Flam T et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. The Journal of urology 2013; 189(2): 493-499.29.Rouse P, Shaw G, Ahmed HU, Freeman A, Allen C, Emberton M. Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urologia internationalis 2011; 87(1): 49-53.30.Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence And Pathologic Features Of Prostate Cancer Detected On Transperineal Template-Guided Mapping Biopsy Following Negative Transrectal Ultrasound-Guided Biopsy. J Urol 2013.31.Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009; 361(17): 1704-1706.32.Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M-O et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011; 60(2): 291-303.33.Wolters T, Roobol MJ, Leeuwen PJv, Bergh RCNvd, Hoedemaeker RF, Leenders GJLHv et al. A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial. JURO 2011; 185(1): 121-125. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- discovery management role office 365
- why discovery worksheet
- 2019 archaeological discovery israel
- discovery education sign up
- ucl msc financial mathematics
- ucl ms finance
- ucl finance msc
- ucl accounting and finance
- ucl financial engineering
- ucl msc computational finance
- ucl statistics economics and finance
- ucl msc engineering with finance